← Search & browse all drugs
NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Selective serotonin (5HT1) agonists
almotriptan
N02CC05
Forms & Strengths
- Tablets: 6.25mg, 12.5mg
- Orally disintegrating tablets: 6.25mg, 12.5mg
Adult Dosing
- Initial dose: 6.25mg to 12.5mg
- May repeat dose after 2 hours if needed
- Maximum dose: 25mg per 24 hours
Pediatric Dosing
- Safety and efficacy not established in patients under 18 years old
Indications
- Acute treatment of migraine attacks with or without aura
- Relief of migraine headache pain
Mechanism of Action
- Selective agonist of 5-HT1B/1D receptors
- Vasoconstrictive effects on intracranial blood vessels
- Inhibition of pro-inflammatory neuropeptide release
Contraindications
- Hypersensitivity to almotriptan
- Ischemic heart disease, coronary artery vasospasm, or other significant cardiovascular disease
- Cerebrovascular disease, including stroke and transient ischemic attack
- Peripheral vascular disease
- Uncontrolled hypertension
- Concurrent or recent use of ergotamines, ergot-type medications, or other 5-HT1 agonists
Adverse Reactions
- Dizziness, somnolence, headache
- Nausea, vomiting, diarrhea
- Paresthesia, fatigue, weakness
- Chest pain, tightness, or pressure
- Myalgia, arthralgia
Drug Interactions
- MAOIs: increased risk of serotonin syndrome
- SSRIs, SNRIs, and other serotonergic agents: increased risk of serotonin syndrome
- Ergotamines and ergot-type medications: increased risk of vasospasm
- Other 5-HT1 agonists: additive vasospastic effects
Curated Content: Needs Vetting Before Put to Clinical Use